Novartis Looks To Enter mRNA Technology, Says Chairman: Reuters

  • Novartis AG NVS could get into the field of messenger ribonucleic acid (mRNA) technology, reported Reuters, citing Chairman Joerg Reinhardt in a newspaper interview.
  • In the Aargauer Zeitung interview, Reinhardt also highlighted the company's interest in anti-infective products that the pandemic has also driven.
  • "Novartis is doing the same, and we are having the discussion this week in the executive committee and then in August in the board of directors," he added without being more specific.
  • "We are now reassessing that," Reinhardt said, as the pandemic has resurrected the company's interest in anti-infectives.
  • In addition to antivirals against the coronavirus developing in a partnership with Molecular Partners AG MLLCF, Novartis is also working on an oral protease inhibitor that it hopes could be effective in a long-term fight against COVID-19.
  • Price Action: NVS shares are up 0.32% at $91.53 during the market session on the last check Thursday.
Loading...
Loading...
MLLCF Logo
MLLCFMolecular Partners AG
$4.22-%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
Not Available
Growth
Not Available
Quality
Not Available
Value
Not Available
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs

Comments
Loading...